{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:12:05Z","timestamp":1792293125489,"version":"4.4.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia-lymphoma (ATL) is an intractable mature T-cell neoplasm. We performed a nationwide retrospective study of allogeneic hematopoietic stem cell transplantation (HSCT) for ATL in Japan, with special emphasis on the effects of the preconditioning regimen. This is the largest study of ATL patients receiving HSCT. Median overall survival (OS) and 3-year OS of bone marrow or peripheral blood transplantation recipients (n = 586) was 9.9 months (95% confidence interval, 7.4-13.2 months) and 36% (32%-41%), respectively. These values for recipients of myeloablative conditioning (MAC; n = 280) and reduced intensity conditioning (RIC; n = 306) were 9.5 months (6.7-18.0 months) and 39% (33%-45%) and 10.0 months (7.2-14.0 months) and 34% (29%-40%), respectively. Multivariate analysis demonstrated 5 significant variables contributing to poorer OS, namely, older age, male sex, not in complete remission, poor performance status, and transplantation from unrelated donors. Although no significant difference in OS between MAC and RIC was observed, there was a trend indicating that RIC contributed to better OS in older patients. Regarding mortality, RIC was significantly associated with ATL-related mortality compared with MAC. In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL.<\/jats:p>","DOI":"10.1182\/blood-2012-03-414490","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:49:44Z","timestamp":1339480184000},"page":"1734-1741","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":157,"title":["Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study"],"prefix":"10.1182","volume":"120","author":[{"given":"Takashi","family":"Ishida","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Hishizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Tanosaki","sequence":"additional","affiliation":[{"name":"Clinical Laboratories Division, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Takatsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sasebo City General Hospital, Sasebo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Kyushu Cancer Center, Fukuoka. Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Morishima","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation Data Management\/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111811352541200_B1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111811352541200_B2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes.","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111811352541200_B3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases.","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"3","key":"2019111811352541200_B4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting.","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"2019111811352541200_B5","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111811352541200_B6","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes.","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111811352541200_B7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature.","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111811352541200_B8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation.","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111811352541200_B9","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma.","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111811352541200_B10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma.","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"2019111811352541200_B11","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111811352541200_B12","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2019111811352541200_B13","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2011-09-379982","article-title":"Cancer\/testis antigens are novel targets of immunotherapy for adult T-cell leukemia\/lymphoma.","volume":"119","author":"Nishikawa","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111811352541200_B14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","article-title":"Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials.","volume":"46","author":"Choi","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111811352541200_B15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/0008-5472.CAN-03-1452","article-title":"Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.","volume":"64","author":"Harashima","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"2019111811352541200_B16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1532\/IJH97.05173","article-title":"Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia.","volume":"83","author":"Hishizawa","year":"2006","journal-title":"Int J Hematol"},{"issue":"12","key":"2019111811352541200_B17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/bmt.2008.39","article-title":"Graft-versus-adult T-cell leukemia\/lymphoma effect following allogeneic hematopoietic stem cell transplantation.","volume":"41","author":"Yonekura","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111811352541200_B18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbmt.2008.04.014","article-title":"A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia\/lymphoma (ATL): clinical impact of graft-versus leukemia\/lymphoma effect.","volume":"14","author":"Shiratori","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8891","key":"2019111811352541200_B19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(94)90994-6","article-title":"Human T-lymphotropic virus type I in Japan.","volume":"343","author":"Yamaguchi","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"2019111811352541200_B20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2019111811352541200_B21","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111811352541200_B22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111811352541200_B23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111811352541200_B24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"1","key":"2019111811352541200_B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/bimj.200900076","article-title":"Competing risks and time-dependent covariates.","volume":"52","author":"Cortese","year":"2010","journal-title":"Biom J"},{"issue":"6","key":"2019111811352541200_B26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111811352541200_B27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"2019111811352541200_B28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians.","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2019111811352541200_B29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians.","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111811352541200_B30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2019111811352541200_B31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12185-011-0802-2","article-title":"Alemtuzumab for the prevention and treatment of graft-versus-host disease.","volume":"93","author":"Kanda","year":"2011","journal-title":"Int J Hematol"},{"issue":"9","key":"2019111811352541200_B32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111811352541200_B33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult t-cell leukemia-lymphoma: a multicenter phase ii study.","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111811352541200_B34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-011-0941-5","article-title":"Antibody therapy for Adult T-cell leukemia-lymphoma.","volume":"94","author":"Ishida","year":"2011","journal-title":"Int J Hematol"},{"issue":"6","key":"2019111811352541200_B35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/ehm.10.73","article-title":"Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches.","volume":"3","author":"Tanosaki","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2019111811352541200_B36","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","article-title":"Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-{alpha}-refractory adult T-cell leukemia.","volume":"106","author":"Mone","year":"2005","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/8\/1734\/1499380\/zh803412001734.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/8\/1734\/1499380\/zh803412001734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:22:46Z","timestamp":1714033366000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/8\/1734\/30830\/Allogeneic-hematopoietic-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,23]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-414490","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,23]]}}}